The latest paper from our STOP-COVID consortium: In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study https://t.co/V36X6ggVcs
Congrats to all the STOP-COVID Investigators on this important work!
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/7tuVKyhUnB via @JAMAInternalMed part of @JAMANetwork
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 https://t.co/fj3rhK5cFS via @JAMAInternalMed part of @JAMANetwork
Congratulations to Dr. Brendan Bowman, Associate Professor, @UVANeph@UvaDOM who is a recipient of the UVA Dean’s Clinical Excellence Award for innovations in clinical nephrology. @MarkOkusa @cavanaugh_do @NephTushar
DNAJB9 is a recently discovered biomarker of fibrillary GN. This discovery has already led to development of tissue biomarker stains. Could DNAJB9 represent a potential target for pharmacologic intervention?
https://t.co/FGrXvwemSr
https://t.co/IG3Vx8ut7l
https://t.co/zMiBUkQXvJ
C#35.FSGS in 45 yr old with recent onset frank nephrotic syn(NS). The nephrologist asked me:primary or secondary? Simple rule of thumb in adults (in absence of diabetes): NS=Primary FSGS; slowly progressive proteinuria (nephrotic range, but not NS)=secondary FSGS. EM very helpful
Congratulations to Dr. Kambiz Kalantari! He was recently elected by the UVA SOM to be the Harrison Distinguished Teaching Associate Professor of Medicine. This endowed chair recognizes a highly accomplished educator in the SOM. @UVANeph